Schofield Lyn, Watson Natasha, Grieu Fabienne, Li Wei Qi, Zeps Nik, Harvey Jennet, Stewart Colin, Abdo Michael, Goldblatt Jack, Iacopetta Barry
School of Surgery, University of Western Australia, Nedlands, Australia.
Int J Cancer. 2009 Mar 1;124(5):1097-102. doi: 10.1002/ijc.23863.
Approximately 1-2% of colorectal cancers (CRC) arise because of germline mutations in DNA mismatch repair genes, referred to as Lynch syndrome. These tumours show microsatellite instability (MSI) and loss of expression of mismatch repair proteins. Pre-symptomatic identification of mutation carriers has been demonstrated to improve survival; however, there is concern that many are not being identified using current practices. We evaluated population-based MSI screening of CRC in young patients as a means of ascertaining mutation carriers. CRC diagnosed in patients aged <60 years were identified from pathology records. No prior information was available on family history of cancer. PCR techniques were used to determine MSI in the BAT-26 mononucleotide repeat and mutation in the BRAF oncogene. Loss of MLH1, MSH2, MSH6 and PMS2 protein expression was evaluated in MSI+ tumours by immunohistochemistry. MSI+ tumours were found in 105/1,344 (7.8%) patients, of which 7 were excluded as possible Lynch syndrome because of BRAF mutation. Of the 98 "red flag" cases that were followed up, 25 were already known as mutation carriers or members of mutation carrier families. Germline test results were obtained for 35 patients and revealed that 22 showed no apparent mutation, 11 showed likely pathogenic mutations and 2 had unclassified variants. The proportion of MSI+ cases in different age groups that were estimated to be mutation carriers was 89% (<30 years), 83% (30-39), 68% (40-49) and 17% (50-59). We recommend MSI as the initial test for population-based screening of Lynch syndrome in younger CRC patients, regardless of family history.
约1%-2%的结直肠癌(CRC)是由DNA错配修复基因的种系突变引起的,称为林奇综合征。这些肿瘤表现为微卫星不稳定性(MSI)和错配修复蛋白表达缺失。已证明对突变携带者进行症状前鉴定可提高生存率;然而,有人担心目前的做法未能识别出许多携带者。我们评估了对年轻患者进行基于人群的CRC的MSI筛查,以此作为确定突变携带者的一种方法。从病理记录中识别出年龄<60岁的CRC患者。此前没有癌症家族史的相关信息。采用聚合酶链反应(PCR)技术测定BAT-26单核苷酸重复序列中的MSI以及BRAF癌基因中的突变。通过免疫组织化学评估MSI+肿瘤中MLH1、MSH2、MSH6和PMS2蛋白表达缺失情况。在1344例患者中有105例(7.8%)发现MSI+肿瘤,其中7例因BRAF突变被排除可能的林奇综合征。在接受随访的98例“红旗”病例中,25例已知为突变携带者或突变携带者家族成员。获得了35例患者的种系检测结果,其中22例未显示明显突变,11例显示可能的致病突变,2例有未分类的变异。估计不同年龄组中MSI+病例为突变携带者的比例分别为89%(<30岁)、83%(30-39岁)、68%(40-49岁)和17%(50-59岁)。我们建议将MSI作为对较年轻CRC患者进行基于人群的林奇综合征筛查的初始检测方法,无论其家族史如何。